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Postoperative radiotherapy in 131 patients with glioblastoma multiforme:
the single institution experience
Lucyna K´pka, Jacek Fijuth, Ewa Wasilewska-TeÊluk1, Czes∏awa Leszczyk
A i m. To evaluate the results and to define the prognostic factors in postoperative radiotherapy of cerebral glioblastomas.
Material and Method. Between 1984 and 1996, 131 patients with glioblastoma multiforme (GBM) were treated in the II
Radiation Oncology Department of the M. Curie-Sklodowska Memorial Cancer Centre in Warsaw. Median age of the patients
was 57 years, median duration of neurologic symptoms – 5 weeks, 30% of the patients had undergone complete surgical exci-
sion of the tumour. Patients received hypofractionated irradiation 20–40 Gy in 3–4 Gy per fraction in 50.5%, 42 Gy in 2.8 Gy
per fractions in 14.5%, and conventional irradiation of 56–62 in 2 Gy per fraction in 34%. Actuarial overall survival was cal-
culated using the Kaplan-Meier method and the log-rank test was used for the comparison of variants.
Re s u l t s. Actuarial overall survival rates at 1 and 2 years were 30- and 7% respectively. Median survival time for all the stu-
died patients was 9 months. Based upon univariate analysis pre-treatment performance status (PPS) and extent of surgery we-
re significant prognostic factors (p=0.02). Actuarial survival rates at 1 and 2 years for patients in WHO PPS 0-1 were 39- and
14%, and for patients in WHO PPS 2–3 they were 16- and 2.5% respectively. Median survival time was 12 months for patients
after complete surgical resections and 6 months for patients after biopsies, partial and subtotal excisions. There was a tenden-
cy towards a longer survival time of younger patients (60 years and less) (p=0.05). Neurological performance status, the si-
ze of the tumour before surgery, and the tumour location were not significantly related to survival.
C o n c l u s i o n s. Survival after postoperative radiotherapy in GBM patients remains poor. The extent of surgery and WHO PPS
were prognostic factors for overall survival. Information gained in a retrospective study, such as this, provides a basis for the
choice of treatment policy in glioblastomas.
Wyniki pooperacyjnej radioterapii u 131 chorych na gàbczaka wielopostaciowego mózgu
C e l  p r a c y. Podsumowanie wyników radioterapii pooperacyjnej chorych na gàbczaka wielopostaciowego mózgu, leczonych
w latach 1984–1996 w naszym oÊrodku i okreÊlenie czynników rokowniczych zwiàzanych z prze˝yciem.
M a t e r i a ∏  i m e t o d a. Analizie poddano 131 chorych napromienianych w II Zak∏adzie Teleradioterapii Centrum Onko-
logii w Warszawie w latach 1984–1996. Mediana wieku analizowanej grupy wynosi∏a 57 lat, mediana trwania dolegliwoÊci neu-
rologicznych – 5 tygodni, 30% chorych napromieniano po zabiegach radykalnych, a 70% po zabiegach subtotalnych, cz´Êcio-
wych i biopsjach. Dawki radioterapii waha∏y si´ od 20 Gy w 5 frakcjach przez 30-36 Gy w 10–12 frakcjach do 60 Gy w 30 frak-
cjach. Prawdopodobieƒstwo prze˝ycia oceniono metodà Kaplana-Meiera. Przy zastosowaniu testu logrank oceniono wp∏yw
na prze˝ycie nast´pujàcych czynników rokowniczych: wieku, stanu ogólnego, stanu sprawnoÊci neurologicznej, lokalizacji no-
wotworu, rozmiarów guza przed zabiegiem neurochirurgicznym, doszcz´tnoÊci zabiegu neurochirurgicznego.
W y n i k i. W badanej grupie oszacowane jednoroczne prze˝ycie wynios∏o 30%, a prze˝ycie dwuletnie – 7%. Mediana prze˝y-
cia wynosi∏a 9 miesi´cy. Statystycznie znamienny wp∏yw na prze˝ycie w analizie jednowymiarowej mia∏y: stan ogólny (p=0,02)
i doszcz´tnoÊç zabiegu neurochirurgicznego (p=0,02). Prze˝ycie jedno-, i dwuletnie dla chorych w stanie ogólnym 0–1 wed∏ug
WHO wynosi∏o odpowiednio 39% i 14%, podczas gdy chorzy w stanie ogólnym 2–3 wg WHO prze˝ywali 1 i 2 lata odpowied-
nio w 16% i w 2,5%. Chorzy po zabiegach makroskopowo radykalnych prze˝ywali 1 i 2 lata w 52% i 10%, podczas gdy jed-
no- i dwuletnie prze˝ycie chorych poddanych zabiegom subtotalnym, cz´Êciowym i biopsjom wynios∏o 16% i 4%. Mediana
prze˝ycia dla chorych po zabiegach radykalnych wynosi∏a 12 miesi´cy, a dla chorych po zabiegach nieradykalnych 6 miesi´-
cy. Zarysowa∏a si´ tendencja do poprawy prze˝ycia w grupie chorych poni˝ej 60 r. ˝. (p=0,05). Pozosta∏e czynniki, jak stan
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Introduction
Despite aggressive treatment prognosis in case of
glioblastoma (GBM) patients remains poor. Postope-
rative radiotherapy has been found to be efficient
in prolonging the median survival time from 6 months
for patients undergoing sole surgery to 8-10 months [1,
2]. Many retrospective studies identified a number of
prognostic factors, which included age at the time of
diagnosis, overall performance status, neurological defi-
cits, tumour size, tumour location and extent of resection
[1, 3, 4, 5]. The partitioning analysis of the outcome
of 1578 patients treated according to RTOG randomised
trials identified 6 prognostic groups based on tumour
histology, age, extent of resection, performance sta-
tus, neurological deficits and mental status [6, 7]. We
review our experience with cerebral glioblastomas tre-
ated between 1984 and 1996 at the II Radiation Oncolo-
gy Department of the M. Sklodowska-Curie Memorial,
Cancer Centre of Oncology in Warsaw. This analysis fo-
cuses on the overall survival time and on the prognostic
factors.
Material and method
Between 1984 and 1996, 161 patients with histologically con-
firmed diagnosis of GBM were referred to our Department.
Thirty patients were excluded from analysis, because 14 had
diagnosis of a distinct variant of GBM – gliosarcoma, 7 were
younger than 16 years, 7 had prior radiotherapy to the brain
because of lower-grade gliomas, 2 discontinued treatment and
were lost from follow-up. Eventually 131 patients were inclu-
ded in the analysis. Pre-radiotherapy patient characteristics are
presented in Table I. Neurological deficit status was assessed
from each patient's medical record according to the
EORTC/MRC score (appendix 1) [8]. The extent of tumour re-
section was defined by the surgeon. Only 57 (44%) patients un-
derwent CT examination after resection in order to assess the
extent of surgery.
Radiotherapy was started 3–6 weeks after surgical treat-
ment (median time: 33 days). Different doses, fractionation
schedules, treatment volumes and possible chemotherapy asso-
ciations were employed. The distribution of patients into the
various treatment groups is summarised in Table II. Schedules
of 5 x 4 Gy and 10 x 4 Gy were designed for the patients with
the poorest prognosis (advanced age and low WHO perfor-
mance status). Schedules of 10-12 x 3 Gy was designed for
younger patients (usually 50 years and less) with a low WHO
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sprawnoÊci neurologicznej, rozmiary guza przed zabiegiem neurochirurgicznym, lokalizacja nowotworu pozosta∏y bez wp∏ywu
na prze˝ycie.
W n i o s k i. Wyniki napromieniania pooperacyjnego u chorych na gàbczaka wielopostaciowego sà z∏e. Zakres operacji i stan
ogólny chorych okaza∏y si´ w naszym materiale najsilniejszymi prognostycznymi czynnikami. ObecnoÊç okreÊlonych czynni-
ków rokowniczych winna determinowaç wybór techniki radioterapii.
S∏owa kluczowe: gàbczak wielopostaciowy, radioterapia, czynniki rokownicze
Key words: glioblastoma, radiotherapy, prognostic factors
Tab. I. Patient characteristics
Variable Category No of patients (percentage) or
* Value for continuous parameters
Sex Male: Female 90 (69%): 41(31.0%)
Age Median (range) * 57 years (19–76)
WHO performance status before the onset 0–1 73 (56.0%)
of radiotherapy 2 38 (29.0%)
3 20 (15.0%)
Neurological deficit status according to EORTC/MRC 1 36 (27.5%)
score before start of radiotherapy 2 34 (26.0%)
3 35 (26.5%)
4 26 (20.0%)
Duration of symptoms before diagnosis Median (range) * 5 weeks (1–50)
Size of tumour on the greatest dimension before ≤5 cm 68 (52.0%)
surgery >5 cm 53 (41.0%)
unknown 9 (7.0%)
Tumour location – frontal 24 (18.3%)
– temporal 26 (20.0%)
– parietal 14 (11.0%)
– occipital 4 (3.0%)
– more than one lobe 62 (47.0%)
– cerebellum 1 (0.7%)
Extent of resection total 35 (26.7%)
partial and subtotal 90 (68.7%)
biopsy 6 (4.6%)
pre-treatment performance status (PPS). Conventional fractio-
nation up to 56–60 Gy was a treatment policy for patients with
a 0–1 WHO PPS. Hypofractionated schedule of 15 x 2.8 Gy was
applied during the last 3 years of the analysed period in a ma-
jority of patients with malignant gliomas and corresponded to
changes in treatment policies related to poorly prognosing
cancer in our institution. Changes in treatment volume from
encompassing the entire brain to the tumour only (with a 2–3
cm margin all around) had also corresponded to the evolu-
tion of treatment policy according to publications which re-
port data supporting the use of partial brain irradiation in this
issue [9]. We have also recommended the use of Lomustine
(CCNU) at the relapse of treatment after radiotherapy. Many
patients with a poor performance status were not fit for this ap-
proach. Some irradiated patients received chemotherapy in
other centres before and/or after radiotherapy. Follow-up infor-
mation was available from charts, all patients had visits schedu-
led at 4–6 weeks after treatment completion and subsequently
every 3 months.
Survival characteristics were calculated according to the
Kaplan-Meier method. The prognostic significance of patient’s
age (≤50 years vs. >50 years and in 3 groups: ≤35 y., 36–60 y.,
and >60 y.), WHO PPS (pre-treatment performance status) (0-
–1 vs. 2–3), status of neurological deficits (EORTC/MRC 1–2 vs.
EORTC/MRC 3-4), tumour size before surgery (≤5 cm vs. >5
cm), tumour location (frontal, temporal, parietal and/or occipi-
tal), extent of tumour resection (total resections vs. subtotal,
partial resections or biopsies) were assessed using the log-rank
test [10]. Survival was measured from the date of the onset of ra-
diotherapy.
Results
There were 128 deaths among analysed patients, 1 pa-
tient is alive (163 months from date of radiotherapy on-
set), 2 were lost from follow-up.
Sixty-six patients (50%) underwent computerrised
tomography examination (CT) of the brain after radiothe-
rapy, but the assessment of the radiotherapy effect was
possible only in 53 (40%) patients of this group with post-
-surgical, pre-irradiation CT scan. In the group of 53 pa-
tients, 22% had complete radiological response, 28% par-
tial response, 28% no change, and 22% progressive dise-
ase. The neurological status improved in 34%, in 44% it
was stable and 34% patients deteriorated.
The 1- and 2-year survivals were 30% and 7%, re-
spectively (Fig. 1), with a median survival of 9 months. Ta-
ble III shows the association of all 6 examined possible
prognostic variables with survival. Of these 6 variables
only the extent of resection (p=0.02) (Fig.2) and WHO
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Tab. II. Radiotherapy techniques, doses and associations with chemotherapy in the analysed group of 131 GBM patients irradiated after surgery
Total dose and fractionation schedule 20 Gy in 5 fractions and 5 days of treatment 7 (5.5%) patients
40 Gy in 10 fractions with a gap of 1 month after 5 fractions 12 (9.0%)
30–39 Gy in 10–13 fractions and 12–16 days 48 (36.5%)
42 Gy in 15 fractions and 19 days 19 (14.5%)
56–62 Gy in 28 –31 fractions and 6 weeks 45 (34.5%)
Treated volume whole brain 55 (42.0%) patients
whole brain to 40–50 Gy with a boost to tumour 43 (33.0%)
limited to tumour volume with 2–3 cm margins 33 (25.0%)
Energy of radiation photons X of 200 keV 12 (9.0%) patients
photons of Co60 85 (65.0%)
photons X of 4 MV, 9MV or 15 MV 20 (15.0%)
Co60 and photons X or electrons 14 (11.0%)
Chemotherapy (CCNU) without chemotherapy 53 (40.5%) patients
before and after radiotherapy 13 (10.0%)
immediately after end of radiotherapy 36 (27.5%)
at relapse 29 (22,0%)
Fig.1. Survival of 131 GBM patients irradiated after surgery in The II
Radation Oncology Department the Maria Sklodowska-Curie Memo-
rial Cancer Centre-Institute of Oncology in Warsaw between 1984 and
1996
PPS (p=0.02) (Fig.3) were significantly associated with
survival in the univariate analysis. Age (≤50 y. vs. >50
y.), neurological deficit status, tumour size before surge-
ry and tumour location did not influence survival. Ho-
wever, there was a tendency towards longer survival times
in younger patients. When three subgroups differing as to
age were identified – (1) to 35 years, (2) 36–60 years, (3)
>60 years, the one-year survival time was 46-, 39-, and
17% respectively. These differences did not reach statisti-
cal significance (p=0.054), mainly because of the small si-
ze of subgroups. Nevertheless, the trend is apparent.
A separate analysis revealed a dose-effect relation-
ship in survival of GBM patients. Median survivals for
patients with fractionation schedules 5 x 4 Gy, 10–12 x 3
Gy, 2 series of 5 x 4 Gy, 15 x 2.8 Gy, 28–31 x 2 Gy were re-
spectively – 3, 7, 9, 9 and 11,5 months. As could be antici-
pated, the groups of patients receiving lower doses had
a lower performance status. The group of patients rece-
iving 5 x 4 Gy frequently succumbed to their disease prior
to achieving all planned course of radiotherapy (2 series
of 5 x 4 Gy). There was an increase in median survival ti-
me in the group of patients receiving chemotherapy (11
months) in comparison to the one without chemotherapy
(6 months). There were 68% patients with WHO PPS 0-
-1 in the chemotherapy group, whilst only 37% in the
group without chemotherapy. The poorer initial perfor-
mance status of patients who received lower doses of ra-
diotherapy and who had never received chemotherapy
did alter the conclusion concerning the possible relation-
ship between the increase of survival and the dose of ra-
diotherapy or addition of chemotherapy to the treatment.
For this reason radiotherapy dose and use of chemothera-
py are not shown in Table III.
We did not observe any significant acute toxicity of
radiotherapy, however 90% of patients received steroids
during treatment. It is difficult to gather from a retro-
spective study such as this, how often was the increase
in steroid use required, and to distinguish treatment rela-
ted oedema symptoms from treatment failures. Late ra-
diological effects of radiotherapy such as cortical atro-
phy, ventricular dilatation and calcifications were discer-
nible in 12 patients (24% of these who had a CT scan
after 6 months and more counting from the onset of ra-
diotherapy). One patient not only presented radiologi-
cal changes but also experienced memory and attention
problems leading to considerable social handicap.
Discussion
Patient characteristics in the presented study did not dif-
fer from that published by other authors. In our expe-
rience, as is the case in literature, GBM occurred more
frequently in men than in women and median age of pa-
tients was 57 years [1, 4, 11]. The median time from symp-
tom onset to diagnosis, known to be one of the shortest
among brain tumours, was 5 weeks [11]. Beyond the short
natural history of the tumour, a large mass with extensive
oedema at presentation is proof of the particular aggres-
siveness of this disease. Only 35% of the tumours are, at
the moment of diagnosis, limited to one lobe [12]. In our
study nearly half of the tumours were multilobed. On
diagnosis the size of the tumour exceeded 5 cm in more
than 50% of the cases and less than 30% of all patients
underwent total resection, which remains in unison with
data reported by other authors [1, 4].
The survival figures for the entire group are similar
to other reports: one-year survivals range from 20 to 40%,
and from 4 to 20% of patients are still alive after 2 years.
Five-year survivals are extremely rare [1, 4, 13]. Despite
intense investigations aiming at the improvement of the
therapeutic ratio of radiotherapy by adding chemothe-
rapy, radiosensitizers and/or alternating fractionation
schedules, the prognosis for GBM patients remains poor
[1, 2, 4, 15]. Radioresistance of GBM and the proven re-
lationship between radiation dose in the range of 40–60
Gy and survival lead to many trials of dose escalations
using different methods [16]. Results of dose escalation
studies using brachytherapy or stereotactic techniques
are not sufficiently convincing [17, 18]. In our study, the
observed improved survival time of patients receiving hi-
gher radiation doses was brought on by pre-treatment
patient selection. As was already mentioned, larger dose
per fraction and lower total doses were prescribed to pa-
tients with discernible poor prognostic factors. Improved
survival of patients treated with chemotherapy in our stu-
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Fig. 2. Survival in the group of 131 GBM patients irradiated after sur-
gery according to the extent of tumour resection: ____ total resections,
------- less than total resections
Fig. 3. Survival in 131 GBM patients irradiated after surgery according
to the WHO performance status: ____ WHO 0–1, ------- WHO 2–3
dy is probably also related to unbalanced performance
status distribution, as explained above. Chemotherapy
did not follow strict treatment protocols. In our institution
chemotherapy was offered at relapse to patients with
a better performance status, while the remaining patients,
with a poor performance status were only offered sup-
portive treatment. About 30% of the patients referred
to our Department for radiotherapy received chemothe-
rapy outside the Institute according to unknown prescrip-
tion criteria. Nevertheless the final analysis has shown
that patients receiving chemotherapy had a slightly su-
perior performance status than those treated with posto-
perative radiotherapy only.
Age, performance status and neurological deficits
are widely recognised as patient related prognostic factors
in the case of brain tumours [3]. Depending on the size of
the presented groups and the manner of data collection
these variables reach different value of statistical signifi-
cance in retrospective series [1, 3, 4]. In our study age
did not reach a statistical significance, while basing upon
RTOG partitioning analysis of randomised trials on mali-
gnant gliomas, a cutpoint value for age was chosen at 50
years [6]. Using this approach to data assessment there
was no difference in one-year survivals, but at two years
patients younger than 50 years had a more favourable
treatment outcome (Table III). It proves that long survi-
vals occur mainly among younger patients. The choice
of the optimal cutpoint value for age in the statistical
analysis of brain tumours remains an unsolved problem.
Gliƒski, following numerous reports, suggests 40 years
of age as the cutpoint used to define the low-risk and
high-risk groups for the prediction of treatment outcome
in cerebral gliomas [1]. Some authors have selected a ran-
ge of age from 60 to 65 years to define the two different
prognostic subgroups for survival, with significant wor-
sening in case of older patients [15, 4]. Our data is similar,
because patients more than 60 years of age revealed a 2-
-year survival time less by twofold as compared to the
two other younger analysed subgroups. We attribute the
lack of statistical significance to the low number of all
three a priori distinguished subgroups. Our study, like
other reports, has shown that the performance status is
a powerful predictor of overall survival. As reported by
Bauman et al. the performance status may be applied
to select a subset of elderly patients who may benefit
from a more intense course of radiation, because in their
study pre-treatment KPS (Karnofsky Performance Sta-
tus) was a more valuable predictor of survival than pa-
tients’ age [19]. Neurological deficit status did not appear
to compromise survival in our study. However, we do
agree that retrospective evaluation of the neurological
status using the medical record of each patient may be too
subjective and deficient, which could be brought on by
the lack of information.
Simpson et al. in an analysis of 645 patients identified
a frontal location of GBM as a positive survival predictor
[4]. Others did not report this feature to be an important
prognostic factor [1]. We did not detect the benefits of
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Tab. III. Influence of selected factors on the survival of 131 GBM patients irradiated after surgery
Variable No of patients One-years Two-years P value Median survival
survival survival
EXTENT OF RESECTION
– total 35 52.0%, 10.0% 0.02 12.0 months
– biopsies, partial, subtotal 96 16.0%, 4.0% 6.0 months
WHO PERFORMANCE STATUS
0–1 73 39.0%, 14.0% 0.02 10.5 months
2–3 58 16.0%, 2.5% 7.0 months
AGE
≤50 years 43 30.0%, 16.0% NS 9.0 months
>50 years 88 28.0%, 3.0% 8.5 months
≤35 years 13 46.0%, 15.0% 0.054 9.5 months
36–60 years 76 39.0%, 12.0% 9.0 months
>60 years 42 17.0%, 0.0% 7.0 months
NEUROLOGIC DEFICIT STATUS
– EORTC/MRC
1–2 Grade 70 33.0%, 10.0% NS 10.0 months
– EORTC/MRC
3–4 Grade 61 25.0%, 3.0% 7.0 months
SIZE OF TUMOUR BEFORE SURGERY
≤5 cm 68 24.0%, 7.5% NS 8.5 months
>5 cm 53 28.0%, 10.0% 7.0 months
TUMOUR LOCATION
Frontal 24 23.0%, 11.0% NS 8.0 months
Temporal 26 22.0%, 11.0% 6.0 months
Parietal and/or Occipital 25 35.0%, 4.0% 10.5 months
any tumour location for survival. Additionally, large volu-
me of tumours associated with frequent involvement of 2-
-3 lobes compromises the use of tumour location for pre-
dictive purposes in GBM. In unison with other reports
a preoperative tumour size was unrelated to survival [4, 5].
In our study the extent of resection was the best pre-
dictor of survival. For irradiated patients the median su-
rvival time after a total resection was twice as long to
that after biopsies and partial and subtotal resections (12
vs. 6 months). Other authors report similar results. Simp-
son et al., mentioned already above, basing upon a large
experience of RTOG trials had shown a positive correla-
tion of the survival time with the extent of resection. Su-
rvival improved from 6.6 to 10.5 months with increased
extent of resection [4]. An analysis of 510 GBM patients
irradiated after surgery by J.R.Wood et al. revealed a ne-
gative correlation of the size of residual tumour with su-
rvival (p<0.0001) [5]. These data support the surgical re-
moval of the greatest possible volume of tumour as safe-
ty allows. Some reports did not find any correlation of
extent of surgery with survival. Gliƒski, basing upon own
experience and a review of published data, explains this
controversy by the inadequate surgical reports of the
extent of resection [1].
It may be concluded that in view of the poor results
with radical radiotherapy in GBM patients with unfavo-
urable prognostic features an abbreviated, palliative tre-
atment may be more appropriate. Patients with favoura-
ble prognostic factors may benefit from carefully desi-
gned clinical trials in view of dose escalation using modern
methods which allow for maximum sparing of healthy tis-
sues. Since April 2000, basing on our-own experience and
published data, mainly the outcome of 1578 malignant
glioma patients treated on consecutive RTOG protocols
and encouraging results of short-course radiotherapy for
poor prognosis GBM patients [6, 7] we have altered our
treatment protocols. Our new treatment policy in cases of
GBM is schematically summarised in Fig.4. The shorte-
ned regimen seems an appropriate treatment option for
GBM patients with the poorest prognosis. New technolo-
gies, such as stereotactic irradiation devices, have bro-
ught on the construction of protocols of dose escalation
for selected GBM patients in view of the improvement of
the irradiation therapeutic ratio.
Conclusions
– The results of postoperative radiotherapy for GBM
patients remain poor.
– The extent of resection, and the WHO performance
status were associated significantly with the survival
of GBM patients irradiated after surgery.
Lucyna K´pka M.D.
Department of Radiotherapy
The Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology,
Roentgena 5, 02-781 Warsaw, Poland
Fig. 4. Treatment policy concerning GBM patients referred to postoperative radiotherapy in the II Radiation Oncology of the Maria 
Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology in Warsaw since April 2000
KPS: Karnofsky Performance Status (appendix 2) [20], y.o.: years old,
# for patients with KPS ≤50 if fit for radiotherapy schedule 5 x 4 Gy is proposed, with eventual second course of 5 x 4 Gy, if improvement of KPS,
* total dose 51Gy in 17 fractions and 5.5 weeks, ^ minimum dose, depending of tumour location
Appendix No 1.
EORTC/MRC Neurological Deficits Score [8].
1. absence of any neurological deficit detectable
2. minor neurological deficits; without any impairment
of normal activity
3. neurological deficits leading to some impairment of
normal activity (paresis, minor mental changes)
4. serious neurological deficits leading to disability to ca-
re for the self: paralysis, aphasia, serious mental (emo-
tional and/or cognitive) changes.
5. any communication with patient impossible
Appendix 2. Karnofsky performance status: 100 point
scale [20]
100. Normal, no complaints, no evidence of disease
90. Able to carry on normal activity, minor signs or
symptoms of disease
80. Normal activity with effort, some signs or symptoms
of disease
70. Cares for self, unable to carry on normal activity,
or do active work
60. Requires occasional assistance, but is able to care for
most needs
50. Requires considerable assistance and frequent me-
dical care
40. Disabled, requires special care and assistance
30. Severely disabled, hospitalisation necessary, altho-
ugh death is not imminent
20. Very sick, hospitalisation necessary, active supportive
treatment necessary
10. Moribund, fatal processes progressing rapidly
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